299 related articles for article (PubMed ID: 30957229)
21. [The Best Time of Minimal Residual Disease Monitoring for Predicting Survival and Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia].
Bao H; Li TY; Wu YT; Xiao ZT; Zhang L; Luo LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1471-1477. PubMed ID: 34627426
[TBL] [Abstract][Full Text] [Related]
22. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
23. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?
Pulsipher MA; Langholz B; Wall DA; Schultz KR; Bunin N; Carroll W; Raetz E; Gardner S; Goyal RK; Gastier-Foster J; Borowitz M; Teachey D; Grupp SA
Bone Marrow Transplant; 2015 Sep; 50(9):1173-9. PubMed ID: 25961775
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
27. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
28. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
29. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
Maloney KW; Devidas M; Wang C; Mattano LA; Friedmann AM; Buckley P; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Kadan-Lottick N; Loh ML; Matloub YH; Marshall DT; Stork LC; Raetz EA; Wood B; Hunger SP; Carroll WL; Winick NJ
J Clin Oncol; 2020 Feb; 38(6):602-612. PubMed ID: 31825704
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
33. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
35. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
37. Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatrics and AYA patients: Single-center Mexican experience.
Colunga-Pedraza JE; González-Llano O; González-Martinez CE; Gómez-Almaguer D; Yáñez-Reyes JM; Jiménez-Antolinez V; Colunga-Pedraza PR
Pediatr Blood Cancer; 2020 May; 67(5):e28241. PubMed ID: 32159276
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
39. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
Kaspers GJL; Niewerth D; Wilhelm BAJ; Scholte-van Houtem P; Lopez-Yurda M; Berkhof J; Cloos J; de Haas V; Mathôt RA; Attarbaschi A; Baruchel A; de Bont ES; Fagioli F; Rössig C; Klingebiel T; De Moerloose B; Nelken B; Palumbo G; Reinhardt D; Rohrlich PS; Simon P; von Stackelberg A; Zwaan CM
Br J Haematol; 2018 May; 181(4):523-527. PubMed ID: 29676440
[TBL] [Abstract][Full Text] [Related]
40. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
